Only patients with continuous Medicare enrollment for 2 years before after HCC diagnosis were examined. Univariate, bivariate and multiple logistic regression analyses were used to evaluate stage of HCC at diagnosis and Kaplan-Meier analyses and unadjusted selleck inhibitor and adjusted Cox proportional hazards regression were
used to assess survival and mortality, respectively. Results: We identified 3,403 diagnosed with HCC between 2004 and 2007 who met our inclusion and exclusion criteria. Nearly a third of the cohort (30%) had hepatitis C virus infection; 26% had a hepatitis B virus infection; 14% had alcoholic liver disease; and 62% had either impaired glucose tolerance or diabetes melli-tus. In multivariable adjusted analysis, receipt of screening tests was associated with HCC stage at diagnosis only among women (Odds Ratio [OR] and 95% confidence interval [95%CI]: 0.62[0.43–0.91]). Among men, only those of Asian race (OR: 0.51; 95% CI: 0.34–0.79) and those with HCV infection (OR: 0.66; 95% CI: 0.48–0.90) had diminished odds of late stage of HCC stage at diagnosis. Among women, being married (OR: 0.61; 95%
CI: 0.41–0.91), or having HCV infection (OR: 0.60; 95% CI: 0.40–0.90), or having alcoholic Daporinad liver disease (OR: 0.45; 95% CI: 0.21–0.94) reduced odds of late stage of HCC at diagnosis. Receipt of routine non-HCC cancer screening tests reduced mortality in both men and women (Hazards Ratio [HR] and [95% CI]: 0.84 [0.72–0.98] and 0.83
[0.70–0.99], respectively). Conclusions: In the Medicare population, older Americans who received receipt of routine non-HCC cancer screening tests in the two years prior to diagnosis find more with HCC experienced an improvement in survival compared to those who did not receive such care. Further studies are needed to examine the mechanism by which receipt of routine non-HCC cancer screening tests improved survival among individuals who developed HCC. Disclosures: C. Daniel Mullins – Consulting: Amgen, Bayer, BMS, Cubist, Eisai, Genentech, Novartis, Otsuka; Grant/Research Support: Bayer, Novartis, Pfizer, Sanofi-Aven-tis, GSK Charles D. Howell – Advisory Committees or Review Panels: Vertex, Inc., Roche-Genetech, Vertex, Inc., Roche-Genetech, Vertex, Inc., Roche-Genetech, Vertex, Inc., Roche-Genetech; Grant/Research Support: Abbott, Eisai, Inc., Abbott, Eisai, Inc., Abbott, Eisai, Inc., Abbott, Eisai, Inc.